Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

A phase II trial of carboplatin in patients with advanced APUD tumors.

Saltz L, Lauwers G, Wiseberg J, Kelsen D.

Cancer. 1993 Jul 15;72(2):619-22.

2.

A phase II trial of streptozotocin and adriamycin in advanced APUD tumors.

Frame J, Kelsen D, Kemeny N, Cheng E, Niedzwiecki D, Heelan R, Lippermann R.

Am J Clin Oncol. 1988 Aug;11(4):490-5.

PMID:
2841843
3.

Therapy of malignant APUD cell tumors. Effectiveness of DTIC.

Kessinger A, Foley JF, Lemon HM.

Cancer. 1983 Mar 1;51(5):790-4.

4.
5.

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.

Varker KA, Campbell J, Shah MH.

Cancer Chemother Pharmacol. 2008 Apr;61(4):661-8. Epub 2007 Jun 23.

PMID:
17589846
6.

Phase II trial of etoposide in APUD tumors.

Kelsen D, Fiore J, Heelan R, Cheng E, Magill G.

Cancer Treat Rep. 1987 Mar;71(3):305-7.

PMID:
2434226
7.

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.

di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A.

Cancer. 1996 Jan 15;77(2):402-8.

8.

Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group.

Neijt JP, Lacave AJ, Splinter TA, Taal BG, Veenhof CH, Sahmoud T, Lips CJ.

Br J Cancer. 1995 Jan;71(1):106-8.

11.

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J.

Cancer. 2001 Apr 15;91(8):1543-8.

PMID:
11301403
12.

Carcinoma of unknown primary site.

Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD.

Cancer. 2000 Dec 15;89(12):2655-60.

PMID:
11135228
13.

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.

Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC.

Cancer. 2005 Oct 15;104(8):1590-602.

15.

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.

Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6111-8.

16.

Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study.

Pavlidis N, Kosmidis P, Skarlos D, Briassoulis E, Beer M, Theoharis D, Bafaloukos D, Maraveyas A, Fountzilas G.

Ann Oncol. 1992 Sep;3(8):631-4.

PMID:
1450045
17.

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.

van Wijk FH, Lhommé C, Bolis G, Scotto di Palumbo V, Tumolo S, Nooij M, de Oliveira CF, Vermorken JB; European Organization for Research and Treatment of Cancer. Gynaecological Cancer Group.

Eur J Cancer. 2003 Jan;39(1):78-85.

PMID:
12504662
18.

Combined carboplatin and cisplatin. Limited prospects for dose intensification.

Waterhouse DM, Reynolds RK, Natale RB.

Cancer. 1993 Jun 15;71(12):4060-6. Review.

19.

Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.

Langer CJ, Leighton J, McAleer C, Comis R, O'Dwyer P, Ozols R.

Semin Oncol. 1995 Jun;22(3 Suppl 6):64-9.

PMID:
7541156
20.

Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.

Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.

Semin Oncol. 1996 Dec;23(6 Suppl 16):35-41.

PMID:
9007119
Items per page

Supplemental Content

Write to the Help Desk